RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Cannabics Pharmaceuticals ROA 2024

Cannabics Pharmaceuticals ROA

-7.42

Cannabics Pharmaceuticals Dividend yield

Ticker

CNBX

ISIN

US13764M1009

WKN

A116WM

In 2024, Cannabics Pharmaceuticals's return on assets (ROA) was -7.42, a 61.56% increase from the -4.59 ROA in the previous year.

Cannabics Pharmaceuticals Aktienanalyse

What does Cannabics Pharmaceuticals do?

Cannabics Pharmaceuticals Inc. is a global company that specializes in the development of personalized therapies using medical cannabis. The company was founded in Israel in 2010 and is headquartered in Tel Aviv. Since then, the company has become a leading player in the medical cannabis industry and has expanded to the United States and Europe. The company's history began with a groundbreaking discovery by the founder's team, who found a method for isolating cannabinoids from cannabis and discovered that cannabinoids have the potential to kill tumor cells. This discovery became the company's passion and they began to focus on the production of personalized therapies using medical cannabis. Cannabics' business model consists of three main divisions: research and development, manufacturing, and commercial distribution of medical cannabis. The company is able to develop personalized therapies that take into account the specific needs of each patient by following a comprehensive approach that considers the specific needs of each patient. Cannabics' research and development department focuses on the development of new personalized therapies and medical devices that include cannabis components. This includes clinical studies to demonstrate the efficacy and safety of cannabis-based medications. The company also works closely with renowned research and development institutions to leverage the latest research and technology. The manufacturing of medical cannabis is another important division of Cannabics. The company operates as a supplier, producing high-quality, personalized cannabis oil specifically tailored to meet the patient's needs. Cannabics works with various strains and cannabis extracts to ensure that each formulation contributes to symptom relief and is safe and effective. Commercial distribution is the third pillar of Cannabics' business model. The company aims to provide its personalized therapies through pharmacies and direct distribution channels to ensure that they reach patients worldwide. Cannabics offers a variety of products, including personalized doses of medical cannabis oil, specific terpene profiles, capsules, extracts, and orally administered medications. The company also offers cannabis tests that are specifically tailored for profiling cancer cells and enabling specific personalization. In recent years, the company has focused on the development of personalized therapies for the treatment of cancer. One of its notable developments is the "Cannabics SR" platform, which provides personalized treatment options for each individual patient based on their cancer genetics. The platform consists of a diagnostic tool to determine the patient's individual cancer and tumor profile. Based on these analyses, the company then formulates a tailored medical treatment using different cannabinoids. Overall, Cannabics Pharmaceuticals Inc. has become a leading company in the medical cannabis industry. The company places a strong emphasis on research and development to develop personalized therapies for the treatment of cancer and other medical conditions and to distribute them worldwide. Cannabics Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Cannabics Pharmaceuticals's Return on Assets (ROA)

Cannabics Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Cannabics Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Cannabics Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Cannabics Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Cannabics Pharmaceuticals Stock

What is the Return on Assets (ROA) of Cannabics Pharmaceuticals this year?

The Return on Assets (ROA) of Cannabics Pharmaceuticals is -7.42 undefined this year.

What was the ROA of Cannabics Pharmaceuticals compared to the previous year?

The ROA of Cannabics Pharmaceuticals has increased by 61.56% compared to the previous year.

What consequences do high ROA have for investors of Cannabics Pharmaceuticals?

A high ROA is advantageous for investors of Cannabics Pharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Cannabics Pharmaceuticals?

A low ROA can be unfavorable for investors of Cannabics Pharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Cannabics Pharmaceuticals affect the company?

An increase in ROA of Cannabics Pharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Cannabics Pharmaceuticals impact the company?

A reduction in the ROA of Cannabics Pharmaceuticals can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Cannabics Pharmaceuticals?

Some factors that can influence the ROA of Cannabics Pharmaceuticals include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Cannabics Pharmaceuticals important for investors?

The ROA of Cannabics Pharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Cannabics Pharmaceuticals take to improve ROA?

To improve ROA, Cannabics Pharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Cannabics Pharmaceuticals pay?

Over the past 12 months, Cannabics Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cannabics Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Cannabics Pharmaceuticals?

The current dividend yield of Cannabics Pharmaceuticals is .

When does Cannabics Pharmaceuticals pay dividends?

Cannabics Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cannabics Pharmaceuticals?

Cannabics Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Cannabics Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cannabics Pharmaceuticals located?

Cannabics Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cannabics Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cannabics Pharmaceuticals from 5/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/10/2024.

When did Cannabics Pharmaceuticals pay the last dividend?

The last dividend was paid out on 5/10/2024.

What was the dividend of Cannabics Pharmaceuticals in the year 2023?

In the year 2023, Cannabics Pharmaceuticals distributed 0 USD as dividends.

In which currency does Cannabics Pharmaceuticals pay out the dividend?

The dividends of Cannabics Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cannabics Pharmaceuticals

Our stock analysis for Cannabics Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cannabics Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.